Wire · opportunities
BioLife patents effervescent oral peptide delivery platform targeting GLP-1 therapies
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 September 2026 · Fusion42 review
BioLife has secured a US patent for its OralMatrix effervescent tablet technology designed to enhance oral peptide delivery and systemic absorption for GLP-1 therapies, addressing a key challenge in peptide drug development. This patent covers several leading GLP-1 drugs and extends patent protection to 2042, signalling potential shifts in oral peptide treatment advances.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can use oral peptide delivery as a new angle to challenge injectable GLP-1 therapies and expand patient access. Patent protection running to 2042 means competitors must innovate around BioLife's platform or risk barriers for a decade.
◆ Coverage
1 source · 11 Sep 2026
◆ Related on Wire
◆ Topics